Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2015

View Archived Issues

Sprint Bioscience and Bayer sign collaboration and license agreement for tumor metabolism program

Apogenix and R-Biopharm partner on companion diagnostics for APG-101

Foundation Medicine initiates study of circulating tumor DNA assay

Oragenics and Intrexon report positive activity for lantibiotics in C. difficile model

PhytoTech Medical completes acquisition of MMJ Bioscience

Viking Therapeutics to conduct phase II study of VK-2809

CDX-085 shows superior bioavailability to microalgal astaxanthin in monkey study

AEterna Zentaris reveals optimized ERK inhibitor and back-up compounds

Sumitomo Dainippon Pharma offers overview of first quarter of fiscal 2015

ARIAD to use ponatinib financing to develop brigatinib

Recombinant protein shows antitumor effect and improves paclitaxel efficacy

Tesaro and Jiangsu Hengrui medicine form rolapitant license agreement for China

Ascendis Pharma reports topline results from a phase II pediatric study of TransCon Growth Hormone

Roche patents neurogenesis-stimulating compounds

Bayer divulges MNK1 inhibitors

Aurigene introduces IRAK-4 inhibitors

Rgenix presents LXR agonists

Piramal patents EZH2 inhibitors

Novel myristoylated peptide aptamer acts as N-type calcium channel blocker for analgesic effects

Roche files PMA for EGFR mutation test as companion diagnostic to AZD-9291

Scripps Florida researchers receive two NIH grants

Scancell and ImmunID to use ImmunTraCkeR to predict response to SCIB-1

GI Dynamics ends pivotal U.S. trial of EndoBarrier

Mayo Clinic and Diadexus collaborate on PLAC Lp-PLA2 test

Eisai files for approval of eribulin in soft tissue sarcoma in U.S., E.U. and Japan

Kyowa Hakko Kirin files for Japanese approval of brodalumab

Takeda Pharmaceutical updates key activities of first quarter of fiscal 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...